Loading
Patient-derived organoids are miniature 3D versions of a patient's tumour grown in the lab.
Patient-derived organoids are grown by stem-cell-driven 3D culture in an extracellular matrix with defined growth factors, so a piece of a patient's tumour becomes a self-renewing miniature that keeps its genotype and drug response. Living biobanks of organoids (HUB, Broad) preserve genotype and drug response across many cancer types. They are used for drug screening, CRISPR studies, and increasingly co-cultured with immune cells for immunotherapy testing. The main limitation is that organoids lack vasculature and the full microenvironment, so stromal and immune effects are only partly captured, and prospective evidence that organoid drug testing improves patient outcomes is still being gathered. For a newcomer, an organoid is a lab-grown copy of one person's tumour that can be tested against drugs before the patient is.
Stem-cell-driven 3D culture in extracellular matrix with defined growth factors.
It offers the first credible explanation for why only a minority of small-cell patients get a durable benefit from checkpoint blockade, and it introduces subtype switching, which would mean retesting at relapse rather than typing once.
Many exciting laboratory findings that motivate drug programmes are weaker or less reliable than published, which helps explain the high failure rate of drugs entering clinical trials. It argues for pre-registration, detailed methods, data sharing and independent replication before major translational investment.
It explains why one biopsy can mislead and why chemotherapy selects for the protective neighbourhood, an argument for spatial rather than bulk profiling.
The organising framework for every small-cell lung cancer trial designed since. It is also why the slow progress in the disease is now attributed to treating four diseases as one rather than to the biology being intractable.
The myCAF and iCAF distinction is why 'target the stroma' became 'target a fibroblast state', and IL-6 blockade combinations follow from it.
It made repeat biopsy and genotyping at progression the standard in ALK-positive lung cancer, because after a second-generation inhibitor the presence or absence of an ALK mutation is what separates patients who should receive a third-generation inhibitor from those who should not.
It made TGF-beta the central target of the microsatellite-stable half of the disease, which is the line that leads to Tauriello's immune-evasion work and to the TGF-beta plus checkpoint combinations in trials.
It is where HER2-directed colorectal therapy came from: the xenopatient result led directly to HERACLES and therefore to every HER2 regimen now used in the disease.
Query for this technology: (TITLE:"patient-derived organoid" OR ABSTRACT:"patient-derived organoid" OR TITLE:"patient-derived organoids" OR ABSTRACT:"patient-derived organoids" OR TITLE:"tumor organoid" OR ABSTRACT:"tumor organoid"). Results are unfiltered search hits about Patient-derived organoids, not a curated reading list.
Shares Tumour-on-a-chip, An independent replication institute that re-tests key preclinical cancer findings before trials, Genetically engineered mouse models, Barcode patient-derived tumours to watch which clones win under each drug.
Shares Build laboratory models of the organs cancer spreads to, Keep a freshly removed tumour alive on a pump and test drugs in it, Test drugs on freshly cut slices of the patient's own tumour, Linked human organ chips to predict side effects before people are dosed.
Shares Cancer cell line encyclopedias and dependency maps, Barcode patient-derived tumours to watch which clones win under each drug, A drug screen that only rewards killing sleeping cancer cells, An open model of every cancer cell state, built from perturbation atlases.
Shares A drug screen that only rewards killing sleeping cancer cells, Make in vivo metastasis screens a required step in drug discovery, A public atlas of drug-pair responses across a thousand patient-derived organoids, An open engine that ranks every drug pair by predicted synergy before anyone runs a trial.
Shares Test drugs on freshly cut slices of the patient's own tumour, Hold organoid drug tests to the same standard as a diagnostic test, Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next.
Shares Pick the laboratory model that matches the patient, not the one to hand, Score every model system on how well it predicted real trial results, An open model of every cancer cell state, built from perturbation atlases, Andrew J. Aguirre.
Shares A bone marrow niche on a chip to study human dormancy, Test drugs on freshly cut slices of the patient's own tumour, An open model of every cancer cell state, built from perturbation atlases, Spatially confined sub-tumor microenvironments in pancreatic cancer.